Electronic Provider Notification to Facilitate the Recognition and Management of Severe Aortic Stenosis: A Randomized Clinical Trial

BACKGROUND: Symptomatic severe aortic stenosis (AS) remains undertreated with high resultant mortality despite increased growth and availability of aortic valve replacement (AVR) since the advent of transcatheter therapies. We evaluate the impact of electronic provider notifications (EPNs) on rates of AVR at 1 year. METHODS: were enrolled. Providers were randomly assigned to receive EPNs for each of their patients with severe AS on TTE or to usual care. Notifications highlighted the detection of severe AS and included patient-specific clinical guideline recommendations for its management. The primary end point was the proportion of patients with severe AS receiving AVR within 1 year of the index TTE. RESULTS: =0.01). CONCLUSIONS: In this first study of EPNs for valvular heart disease, EPNs increased rates of AVR for severe AS, lessened sex and age disparities in AVR use, and improved survival time. EPNs may be a simple, scalable intervention to raise awareness of critical TTE findings and improve the quality of care for patients with severe AS. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05230225.